Up to 44 percent of papillary thyroid cancer patients have a B - raf mutation that can be specifically targeted by existing cancer drugs. (sciencedaily.com)
In fact, the 25 - year survival rate for patients with papillary thyroid cancer, the most common type, is 95 %. (health.com)
Unique Biomarkers Identified for Use in Thyroid Cancer Follow - Up January 2017 Researchers have identified two unique biomarkers that show promise for monitoring patients who have received treatment for papillary thyroid cancer (PTC), according to a study recently published in the new open access Journal of the Endocrine Society... (endocrine.org)